{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T18:27:29Z","timestamp":1785176849830,"version":"3.55.0"},"reference-count":17,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T00:00:00Z","timestamp":1468022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:p>Cytarabine syndrome is a rare clinical condition characterized by fever, malaise, myalgia, arthralgia, and\/or rash that occurs after receipt of cytarabine. Our patient developed fever, malaise, and diffuse body pain shortly following cytarabine initiation despite receiving prophylactic dexamethasone. The patient\u2019s discomfort was treated with intravenous morphine and her other symptoms were controlled with a higher dose of dexamethasone. Although the exact cause is not fully understood, cytarabine syndrome is hypothesized to be an immune-mediated response following cytarabine-induced apoptosis that results in a rapid increase in proinflammatory cytokines. While there is no standard therapy for cytarabine syndrome, corticosteroids appear to play a role in the treatment and prevention of the condition by suppressing the proinflammatory response. Since our case describes the development of cytarabine syndrome despite dexamethasone, clinicians should monitor for this adverse event if patients begin exhibiting characteristics of this syndrome.<\/jats:p>","DOI":"10.1177\/1078155215607090","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T20:21:21Z","timestamp":1443558081000},"page":"795-800","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Cytarabine syndrome despite corticosteroid premedication in an adult undergoing induction treatment for acute myelogenous leukemia"],"prefix":"10.1177","volume":"22","author":[{"given":"Matthew A","family":"Jirasek","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Scott & White Memorial Hospital, Baylor Scott & White Health, Temple, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon D","family":"Herrington","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Scott & White Memorial Hospital, Baylor Scott & White Health, Temple, TX, USA"},{"name":"Department of Medicine, Health Science Center, Texas A&M University, Temple, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,7,9]]},"reference":[{"key":"bibr1-1078155215607090","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950090309"},{"key":"bibr2-1078155215607090","first-page":"405","volume":"67","author":"Shah S","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"bibr3-1078155215607090","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1985.tb02773.x"},{"key":"bibr4-1078155215607090","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04422.x"},{"key":"bibr5-1078155215607090","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60254-2"},{"key":"bibr6-1078155215607090","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.1230"},{"key":"bibr7-1078155215607090","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5832.115"},{"key":"bibr8-1078155215607090","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200501000-00008"},{"key":"bibr9-1078155215607090","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851101)56:9<2181::AID-CNCR2820560907>3.0.CO;2-B"},{"key":"bibr10-1078155215607090","doi-asserted-by":"publisher","DOI":"10.1007\/BF03003180"},{"key":"bibr11-1078155215607090","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07895.x"},{"key":"bibr12-1078155215607090","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(08)60703-4"},{"key":"bibr13-1078155215607090","first-page":"1143","volume":"10","author":"Hedley DW","year":"1996","journal-title":"Leukemia"},{"key":"bibr14-1078155215607090","doi-asserted-by":"publisher","DOI":"10.1042\/bj3201005"},{"key":"bibr15-1078155215607090","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.17.1.f132"},{"key":"bibr16-1078155215607090","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5234.283"},{"key":"bibr17-1078155215607090","first-page":"672","volume":"167","author":"Tay J","year":"2002","journal-title":"CMAJ"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215607090","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155215607090","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215607090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:16:26Z","timestamp":1777688186000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155215607090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,9]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1177\/1078155215607090"],"URL":"https:\/\/doi.org\/10.1177\/1078155215607090","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,9]]}}}